FDA approval
Colin Kerr
Published: Wednesday, May 1, 2019
Aerie Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Rocklatan™ to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
“Rocklatan is a once-daily eye drop that is a fixed-dose combination of latanoprost and netarsudil, the active ingredient in Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork. Rhopressa works by restoring outflow through the trabecular meshwork, while latanoprost increases fluid outflow through the uveoscleral pathway,” said a company spokesman.
www.aeriepharma.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.